Reemergence of stroke deficits with midazolam challenge

Ronald M. Lazar, Brian Fred Fitzsimmons, Randolph S. Marshall, Mitchell F. Berman, Maria A. Bustillo, William L. Young, J. P. Mohr, Jinesh Shah, Julie V. Robinson

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Background and Purpose-Patients who have sustained a neurological injury and then improved may experience transient reemergence of their syndromes when given benzodiazepines. As a step toward assessing whether neurotransmitter systems underlie poststroke clinical improvement, we selected midazolam, a γ-aminobutyric acidA (GABAA) agonist, for systemic administration to measure general or stroke-specific effects in patients. Methods-Eight patients with image-verified stroke (5 with left-sided and 3 with right-sided cerebral lesions) participated. The strokes had occurred from 7 days to 6 years earlier, with patients showing clinical improvement from their initial syndromes. Each patient underwent baseline testing for motor function, aphasia, and left hemispatial neglect, after which intravenous midazolam was delivered until mild drowsiness was detected. Patients were tested during this period and again after 2 hours when sedation had dissipated. Results-After the administration of midazolam, the 5 patients with left hemisphere stroke demonstrated reemergence or worsening of their initial right hemiparesis and aphasia but showed no left neglect. The 3 patients with right cerebral stroke showed reemergence of left hemiparesis and left visual field neglect but no aphasia. All patients returned to baseline after 2 hours. Conclusions-Under conditions of light sedation, patients whose initial stroke syndrome had substantially improved clinically showed transient reemergence of their initial focal syndrome. These data suggest a possible role for GABAA-mediated neurochemical mechanisms in poststroke improvement and sensitivity to medication effects.

Original languageEnglish (US)
Pages (from-to)283-285
Number of pages3
JournalStroke
Volume33
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Midazolam
Stroke
Aphasia
Paresis
Perceptual Disorders
Broca Aphasia
GABA-A Receptor Agonists
Sleep Stages
Patient Rights
Visual Fields
Benzodiazepines
Neurotransmitter Agents
Light
Wounds and Injuries

Keywords

  • Cognition
  • GABA
  • Midazolam
  • Stroke outcome

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Lazar, R. M., Fitzsimmons, B. F., Marshall, R. S., Berman, M. F., Bustillo, M. A., Young, W. L., ... Robinson, J. V. (2002). Reemergence of stroke deficits with midazolam challenge. Stroke, 33(1), 283-285. https://doi.org/10.1161/hs0102.101222

Reemergence of stroke deficits with midazolam challenge. / Lazar, Ronald M.; Fitzsimmons, Brian Fred; Marshall, Randolph S.; Berman, Mitchell F.; Bustillo, Maria A.; Young, William L.; Mohr, J. P.; Shah, Jinesh; Robinson, Julie V.

In: Stroke, Vol. 33, No. 1, 2002, p. 283-285.

Research output: Contribution to journalArticle

Lazar, RM, Fitzsimmons, BF, Marshall, RS, Berman, MF, Bustillo, MA, Young, WL, Mohr, JP, Shah, J & Robinson, JV 2002, 'Reemergence of stroke deficits with midazolam challenge', Stroke, vol. 33, no. 1, pp. 283-285. https://doi.org/10.1161/hs0102.101222
Lazar RM, Fitzsimmons BF, Marshall RS, Berman MF, Bustillo MA, Young WL et al. Reemergence of stroke deficits with midazolam challenge. Stroke. 2002;33(1):283-285. https://doi.org/10.1161/hs0102.101222
Lazar, Ronald M. ; Fitzsimmons, Brian Fred ; Marshall, Randolph S. ; Berman, Mitchell F. ; Bustillo, Maria A. ; Young, William L. ; Mohr, J. P. ; Shah, Jinesh ; Robinson, Julie V. / Reemergence of stroke deficits with midazolam challenge. In: Stroke. 2002 ; Vol. 33, No. 1. pp. 283-285.
@article{a7fd1298ac58438caa833161d58b4015,
title = "Reemergence of stroke deficits with midazolam challenge",
abstract = "Background and Purpose-Patients who have sustained a neurological injury and then improved may experience transient reemergence of their syndromes when given benzodiazepines. As a step toward assessing whether neurotransmitter systems underlie poststroke clinical improvement, we selected midazolam, a γ-aminobutyric acidA (GABAA) agonist, for systemic administration to measure general or stroke-specific effects in patients. Methods-Eight patients with image-verified stroke (5 with left-sided and 3 with right-sided cerebral lesions) participated. The strokes had occurred from 7 days to 6 years earlier, with patients showing clinical improvement from their initial syndromes. Each patient underwent baseline testing for motor function, aphasia, and left hemispatial neglect, after which intravenous midazolam was delivered until mild drowsiness was detected. Patients were tested during this period and again after 2 hours when sedation had dissipated. Results-After the administration of midazolam, the 5 patients with left hemisphere stroke demonstrated reemergence or worsening of their initial right hemiparesis and aphasia but showed no left neglect. The 3 patients with right cerebral stroke showed reemergence of left hemiparesis and left visual field neglect but no aphasia. All patients returned to baseline after 2 hours. Conclusions-Under conditions of light sedation, patients whose initial stroke syndrome had substantially improved clinically showed transient reemergence of their initial focal syndrome. These data suggest a possible role for GABAA-mediated neurochemical mechanisms in poststroke improvement and sensitivity to medication effects.",
keywords = "Cognition, GABA, Midazolam, Stroke outcome",
author = "Lazar, {Ronald M.} and Fitzsimmons, {Brian Fred} and Marshall, {Randolph S.} and Berman, {Mitchell F.} and Bustillo, {Maria A.} and Young, {William L.} and Mohr, {J. P.} and Jinesh Shah and Robinson, {Julie V.}",
year = "2002",
doi = "10.1161/hs0102.101222",
language = "English (US)",
volume = "33",
pages = "283--285",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Reemergence of stroke deficits with midazolam challenge

AU - Lazar, Ronald M.

AU - Fitzsimmons, Brian Fred

AU - Marshall, Randolph S.

AU - Berman, Mitchell F.

AU - Bustillo, Maria A.

AU - Young, William L.

AU - Mohr, J. P.

AU - Shah, Jinesh

AU - Robinson, Julie V.

PY - 2002

Y1 - 2002

N2 - Background and Purpose-Patients who have sustained a neurological injury and then improved may experience transient reemergence of their syndromes when given benzodiazepines. As a step toward assessing whether neurotransmitter systems underlie poststroke clinical improvement, we selected midazolam, a γ-aminobutyric acidA (GABAA) agonist, for systemic administration to measure general or stroke-specific effects in patients. Methods-Eight patients with image-verified stroke (5 with left-sided and 3 with right-sided cerebral lesions) participated. The strokes had occurred from 7 days to 6 years earlier, with patients showing clinical improvement from their initial syndromes. Each patient underwent baseline testing for motor function, aphasia, and left hemispatial neglect, after which intravenous midazolam was delivered until mild drowsiness was detected. Patients were tested during this period and again after 2 hours when sedation had dissipated. Results-After the administration of midazolam, the 5 patients with left hemisphere stroke demonstrated reemergence or worsening of their initial right hemiparesis and aphasia but showed no left neglect. The 3 patients with right cerebral stroke showed reemergence of left hemiparesis and left visual field neglect but no aphasia. All patients returned to baseline after 2 hours. Conclusions-Under conditions of light sedation, patients whose initial stroke syndrome had substantially improved clinically showed transient reemergence of their initial focal syndrome. These data suggest a possible role for GABAA-mediated neurochemical mechanisms in poststroke improvement and sensitivity to medication effects.

AB - Background and Purpose-Patients who have sustained a neurological injury and then improved may experience transient reemergence of their syndromes when given benzodiazepines. As a step toward assessing whether neurotransmitter systems underlie poststroke clinical improvement, we selected midazolam, a γ-aminobutyric acidA (GABAA) agonist, for systemic administration to measure general or stroke-specific effects in patients. Methods-Eight patients with image-verified stroke (5 with left-sided and 3 with right-sided cerebral lesions) participated. The strokes had occurred from 7 days to 6 years earlier, with patients showing clinical improvement from their initial syndromes. Each patient underwent baseline testing for motor function, aphasia, and left hemispatial neglect, after which intravenous midazolam was delivered until mild drowsiness was detected. Patients were tested during this period and again after 2 hours when sedation had dissipated. Results-After the administration of midazolam, the 5 patients with left hemisphere stroke demonstrated reemergence or worsening of their initial right hemiparesis and aphasia but showed no left neglect. The 3 patients with right cerebral stroke showed reemergence of left hemiparesis and left visual field neglect but no aphasia. All patients returned to baseline after 2 hours. Conclusions-Under conditions of light sedation, patients whose initial stroke syndrome had substantially improved clinically showed transient reemergence of their initial focal syndrome. These data suggest a possible role for GABAA-mediated neurochemical mechanisms in poststroke improvement and sensitivity to medication effects.

KW - Cognition

KW - GABA

KW - Midazolam

KW - Stroke outcome

UR - http://www.scopus.com/inward/record.url?scp=0036144168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036144168&partnerID=8YFLogxK

U2 - 10.1161/hs0102.101222

DO - 10.1161/hs0102.101222

M3 - Article

VL - 33

SP - 283

EP - 285

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 1

ER -